Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eisai Ltd ADR (OP: ESALY )

61.51 UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 61.51
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 61.51
Today's Range 61.51 - 61.51
52wk Range 36.88 - 73.90
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Medtronic, Merck, Williams Companies And More: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Anastasia Amoroso of JPMorgan Private Bank named iShares 7-10 Year Treasury Bond ETF (NASDAQ: IEF) 
Via Benzinga
After Back To Back Failure For Keytruda Plus Lenvima, Merck Touts Durable Clinical Benefit For The Combo In Advanced Kidney Cancer
 
Via Benzinga

Performance

YTD
-7.29%
-7.29%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
-13.53%
-13.53%
1 Year
+54.59%
+54.59%

More News

Read More
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
Via Benzinga
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
Via Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
Via Benzinga
Daily Stock Analysis: Eisai
Via Talk Markets
Lecanemab Receives Priority Review Status in Japan
From Eisai
Via JCN Newswire
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
From Eisai
Via JCN Newswire
Tesla Manufactured 4,000 Model Ys In One Week, UBS Prepping For Massive Layoffs, McDonald's Temporary Shuttering Of US Offices: Today's Top Stories
Via Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
Via Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
Via Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
Via InvestorPlace
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
From Eisai
Via JCN Newswire
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
Via Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
Via Benzinga
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
Via Benzinga
Why Anavex Life Sciences Stock Bolted Higher in January
Via The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
Via The Motley Fool
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug
Via Investor's Business Daily
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
Via The Motley Fool
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
Via The Motley Fool
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
Via The Motley Fool
Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill
Via Benzinga
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.